Source comparison
CJC-1295 No DAC vs DAC: Dose Count and Frequency Implications
CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6–8 days, allowing once- or twice-weekly dosing. CJC-1295 no DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple administrations per week to maint
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6–8 days, allowing once- or twice-weekly dosing. CJC-1295 no DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple administrations per week to maintain elevated growth hormone levels. Typically 2–3 times weekly in research protocols.
- This half-life difference directly affects how many doses a single vial supports across a research timeline. A 2mg vial of CJC-1295 with DAC dosed at 2000mcg once weekly yields one dose per vial. An entire vial per administration. The same 2mg vial of CJC-1295 no DAC dosed at 200mcg three times weekly yields 10 doses, covering just over three weeks of a protocol.
- The 'no DAC' variant is preferred in pulsatile growth hormone research because its short half-life mimics natural GH secretion patterns. Peak and trough rather than sustained elevation. The trade-off is dosing frequency: where one vial of the DAC variant covers one week, one vial of the no-DAC variant at equivalent weekly peptide load (600mcg total per week vs 2000mcg once-weekly) covers multiple weeks but requires more frequent administration.
- Cost per protocol cycle favours no-DAC for this reason. A 12-week research model using CJC-1295 with DAC at 2mg weekly requires 12 vials. The same model using CJC-1295 no DAC at 200mcg three times weekly (600mcg weekly total) requires approximately 4 vials. Dose count per vial matters less than total peptide consumption across the full protocol timeline.